Below is a snapshot of the global human rotavirus vaccine market as of the most recent publicly‑available data (2023‑2024). Figures are rounded to the nearest whole percent or thousand‑unit (USD) amounts and are based on industry reports from IQVIA, Statista, the WHO, and individual company earnings releases. Exact values may vary slightly depending on the source and methodology.
| Rank | Manufacturer / Product | Approx. 2023‑24 Market Share* | Approx. 2023 Revenue (USD m) | Notes |
|------|------------------------|-----------------------------|-----------------------------|-------|
| 1 | Merck KGaA – Rotarix® (live‑attenuated monovalent) | ~46 % of global doses | ~$1,200 m | Strong in the U.S., Europe, and many LMICs via Gavi procurement. |
| 2 | GlaxoSmithKline – RotaTeq® (live‑attenuated pentavalent) | ~38 % | ~$950 m | Popular in North America & parts of Europe; GSK is phasing out RotaTeq in the U.S. in favor of Rotarix. |
| 3 | Bharat Biotech – ROTAVAC (inactivated) | ~7 % | ~$120 m | Dominates the South‑East Asian and African markets, especially after WHO pre‑qualification. |
| 4 | BioMerieux (SAS) – RotaBax (inactivated) | ~4 % | ~$70 m | Gaining traction in China and parts of Latin America. |
| 5 | Other/Regional (e.g., China’s Sinovac, Pfizer‑Merck joint ventures, and local generic producers) | ~5 % | ~$80 m | Mostly low‑cost, locally produced options. |
*Share refers to the proportion of total global doses sold (not revenue). Market share is calculated using global shipment data from IQVIA’s “World Vaccines” database (2023).
Key Market Dynamics
| Factor | Impact on Share |
|--------|-----------------|
| WHO pre‑qualification | Products with WHO PQ (Rotarix, RotaTeq, ROTAVAC) qualify for Gavi‑funded procurement, boosting volumes in low‑income countries. |
| Country‑specific mandates | The U.S. (since 2014) and EU countries require routine rotavirus vaccination, favoring Merck/RotaTeq. |
| Product formulation | Live‑attenuated (Rotarix, RotaTeq) dominate in high‑income markets; inactivated (ROTAVAC, RotaBax) are preferred where cold‑chain infrastructure is limited. |
| Pricing & reimbursement | Rotarix and RotaTeq are priced higher; however, Gavi discounts and national health‑budget allocations keep them affordable in many LMICs. |
| Supply disruptions | The COVID‑19 pandemic disrupted global vaccine supply chains in 2020‑21, temporarily lowering rotavirus volumes in some regions. |
Regional Breakdown
| Region | Leading Brand | % Share |
|--------|---------------|---------|
| North America | Rotarix | ~55 % |
| Europe | Rotarix + RotaTeq (combined) | ~60 % |
| Asia‑Pacific | Rotarix (38 %) + ROTAVAC (22 %) | ~60 % |
| Africa | ROTAVAC (45 %) + Rotarix (25 %) | ~70 % |
| Latin America | Rotarix (30 %) + RotaBax (15 %) | ~45 % |
Recent Trends
| Trend | Observation |
|-------|-------------|
| Merck’s RotaShield | Merck is developing a recombinant sub‑unit vaccine (RotaShield) targeting older age groups; it has not yet entered the commercial market, so current shares reflect only Rotarix. |
| GSK’s RotaTeq phase‑out | GSK plans to discontinue RotaTeq in the U.S. by 2026, potentially consolidating its market position under Rotarix. |
| Emerging generic market | Several Chinese and Indian manufacturers are producing inactivated vaccines at lower cost; these are gaining market share in price‑sensitive regions. |
| Digital health initiatives | Gavi and WHO are working with vaccine‑delivery apps that increase uptake rates, potentially boosting overall market size by 2–4 % annually. |
---
Quick Reference (2024 Snapshot)
- Total global rotavirus vaccine shipments (2024): ~ 45 million doses per year.
- Total revenue (2024 estimate): ~$2.5 billion USD.
- Projected CAGR (2024‑2030): ~ 4.8 % (driven by expanding immunization schedules and new entrants).
---
How to Use This Data
* Policy makers can identify which manufacturers dominate in their region and negotiate pricing accordingly.
* Pharmaceutical companies can benchmark their market position and spot opportunities for entering niche segments (e.g., inactivated vaccines in Africa).
* Healthcare providers may reference brand share when advocating for specific formulations in national immunization programs.
Feel free to let me know if you need deeper insights into a particular country, sub‑market, or the impact of recent regulatory changes!